

Schedule	Sunday, 28th Nov.	Monday, 29th Nov.	Tuesday, 30th Nov.	Wednesday, 1st Dec.	Thursday, 2nd Dec.	Friday, 3rd Dec.	Saturday, 4th Dec.	
8:30-9:00		Abdala vaccine, the first Latin American vaccine against COVID-19 <b>Miladys LIMONTA</b> Cuba	<b>Luca Giustini</b> USA Undefined yet	Cost of Quality: human error prevention and reduction, and history of the quality movement <b>Willis THOMAS</b> USA	<b>Alistair HURT</b> Germany Undefined yet	Lentiviral vector reference material <b>Keith CARSON</b> USA		
9:05-9:35	Travel Havana-Varadero	Fermentation process for production of recombinant SARS CoV-2-spike receptor binding domain on <i>Pichia pastoris</i> platform <b>Juan RIVERA</b> Cuba	SARS-CoV-2 nucleocapsid protein elicits a diversified strong humoral response in COVID-19 convalescent patients <b>Rodolfo VALDÉS</b> Cuba	Peptide therapeutic drugs: The fastest way from research to production <b>Hilda GARAY</b> Cuba	Evaluation of an alternative activation and immobilization method for CB.Hep-1 mAb immunosorbent using Zetarose CL4B <b>Mayté QUINTANA</b> Cuba	Updating of good manufacturing practices requirements in Cuba for biological products <b>Biorkys YÁNEZ</b> Cuba		
9:40-10:10		Purification of SARS-CoV-2 RBD antigen <b>Ernesto URRUTIA</b> Cuba	<i>Nicotiana benthamiana</i> plants as bioreactor: SARS-CoV-2 RBD production as study case <b>Abel HERNÁNDEZ</b> Cuba	Elaboration of lipid nanoparticles for mRNA vaccines <b>Carter LOSCH</b> Germany	Determination of absolute protein concentration by amino acid analysis of recombinant protein reference materials <b>Yanet TAMBARA</b> Cuba	Novel trends in Cuban biotechnology industry: Application of risk analysis to release active pharmaceutical ingredients <b>Danelys VELÁZQUEZ</b> Cuba		
10:15-10:45		Abdala vaccine candidate, a productive challenge <b>Carmen CHUAY</b> Cuba	Characterization by mass spectrometry of the recombinant protein RBD obtained in different expression systems <b>Ivan ANDUJAR</b> Cuba	A low-molecular-weight leukocyte extract obtaining by ultrafiltration with immunomodulatory properties <b>Eduardo SÁNCHEZ</b> Cuba	Formulation development of a growth hormone releasing Hexapeptide: characterization insights <b>Hector SANTANA</b> Cuba	<b>Risk Management</b> <b>Steve OLSON</b> USA		
10:50-11:20		Quality control of Cuban vaccine candidates against COVID-19, a battle against time <b>Lourdes COSTA</b> Cuba	NasalFERON, formulation that contains Interferon alfa 2b for COVID-19 prophylactic treatment <b>Ana AGUILERA</b> Cuba	Doses study of the CIGB550-E7 vaccine candidate with alum adjuvant in the TC-1 model <b>Nadia RODRIGUEZ</b> Cuba	Multilayer filtration as clarification step in VLP purification protocol <b>Elias NELSON</b> Cuba	Vaccine technology in human and animal health <b>Pilar RODRÍGUEZ</b> Cuba		
11:25-11:40			Coffee-Break					
11:45-12:15			Immunogenicity, antigenicity and molecular integrity tests of a vaccine candidate against SARS-CoV-2 infection <b>Mabel IZQUIERDO</b> Cuba	LC-MS/MS analyses for identification of conjugation sites, side reactions, and reproducibility evaluation in conjugate vaccines <b>Luis JAVIER</b> Cuba	E2-CD154 vaccine candidate is safe and immunogenic in pregnant sows, and maternal derived neutralizing antibodies protect piglets from CSFV challenge <b>Danny PÉREZ</b> Cuba	Raw material chemical analysis <b>José ZARAZÚA</b> Mexico	Jusvinza, an altered peptide ligand against hyper-inflammation induced by SARS-CoV-2, is safe in <i>Macaca fascicularis</i> <b>Jorge CASTRO</b> Cuba	
12:20-12:50			AICA. Enters into the world of biotechnology and vaccines. A growing partnership with CIGB <b>Emilio VALLÍN</b> Cuba	Determination of elemental impurities in pharmaceutical samples by ICP techniques <b>Rodrigo MORETTO</b> Brazil	High performance electrophoresis applied as 2D PAGE and Western Blotting in HCP analysis <b>Mechtild HOFMANN</b> Germany	All molecular solutions under one roof is what HiGenoMB is all about <b>Susanne FRASH</b> Germany	Cuba engineering activity in pharmaceutical industry: technological maintenance or effective support to processes? study case <b>Tania DE LA CRUZ</b> Cuba	
12:55-1:25			Global regulatory requirements for anti COVID-19 vaccines <b>Javier VÁZQUEZ</b> Cuba	BIACORE experiments in physicochemical characterization of drug substances that involve protein-protein interaction in their biological activity <b>Ania CABRALES</b> Cuba	Host contaminant analysis <b>Moises LÓPEZ</b> Mexico	Software validation and data management <b>Antonio CORTES</b> Spain	Preformulation studies and real time stability of the Heberprovac for cancer prostate treatment <b>Matilde LÓPEZ</b> Cuba	
1:30-3:00		Lunch						
3:05-3:35		Production of recombinant human IFN-gamma and HeberFERON <b>Gustavo FURRAZOLA</b> Cuba	Mass spectrometric characterization of low-abundance species in active pharmaceutical ingredient of synthetic peptides <b>Vladimir BESADA</b> Cuba	Technologies and products to support biotechnological product manufacturing <b>Peter GURSKÉ</b> Germany	Analytical method validation: Overview and regulatory requirements expectations <b>Luis OJEDA</b> Spain	The cocoon of transgenic silkworms as a suitable system for obtaining heterologous proteins of pharmaceutical interest <b>Lianet RODRÍGUEZ</b> Cuba		
3:40-4:10		HeberFERON. From desktop to medical practices <b>Iraldo BELLO</b> Cuba	Analytical instrumentation and more for quality and process control <b>Peter GURSKÉ</b> Germany	Aliam: automation integral solutions <b>Oliva BLANCK</b> Switzerland	Aseptic process validation. Media fill design in a multiproduct plant. A real case study <b>Raúl FERNÁNDEZ</b> Spain	Heberprot-P Technological details, a therapy to treat diabetic foot ulcers (DFU), and its use in the Cuban integral care program for patients with DFU <b>Manuel RAICES</b> Cuba	Travel Varadero-Havana	
5:00-5:30	Venue Information Program Presentation <b>Rodolfo VALDÉS</b> Cuba							
5:30-6:30	Building Biotech Products <b>Key Lecture</b> <b>Jorge VEGA</b> Cuba					Biomanufacturing 2021 Closing Biomanufacturing 2023 Launching <b>Rodolfo VALDÉS</b> Cuba		
6:30-7:00	Special Cultural Moment							

SCHEDULE	Recorded Presentation (TV-1)	Recorded Presentation (TV-2)	Recorded Presentation (TV-3)	Recorded Presentation (TV-4)	
Monday Tuesday Wednesday Thursday	8:30 - 8:45	Monoclonal and polyclonal antibodies as biological reagents for SARS-CoV-2 diagnosis through nucleocapsid protein detection <b>Daily HERNÁNDEZ</b> Cuba	Production of Bacterially-expressed CIGB-247 recombinant antigen for the HEBERSaVax VEGF active immunotherapy <b>Aniurka PANFET</b> Cuba	Consistency of the Heberprot-P® manufacturing process <b>Vivian PUJOL</b> Cuba	Certification by CECMED of the CIGB-814 peptide reference material used in Jusvinza® analytical release <b>Cristina RODRÍGUEZ</b> Cuba
	8:50 - 9:05	Comparison between convalescent plasma and purified immunoglobulins to recognize SARS-CoV-2 S-protein linear peptides <b>Sigifredo PADILLA</b> Cuba	Implementation of a purification method for an antigen of an immune checkpoint molecule-based cancer therapeutic vaccine <b>Camila CANAÁN</b> Cuba	Validation of Heberprot-P active pharmaceutical ingredient by the HPLC-RP analytical technique <b>Jennifer ROJAS</b> Cuba	Trend analysis of environmental microbiological control of a biopharmaceutical plant in its three operational conditions <b>Biunayki REYES</b> Cuba
	9:10 - 9:25	Recombinant protein expression in HEK293 cells to obtain a vaccine candidate against SARS-CoV-2 based on the N-protein <b>Thailin La O</b> Cuba	Immunogenicity and thermal stability of the Porvac® protein subunit vaccine formulation stored at 25 Celsius degrees for twelve months <b>Yusmel SORDO</b> Cuba	Elimination and exchange of trifluoroacetate counter-ion in a cationic peptide: improvements in the process <b>Ever PÉREZ</b> Cuba	Methodology based on risk analysis to turn a dedicated plant into a multi-product plant <b>Milda PÉREZ</b> Cuba
	9:30 - 9:45	Preformulation study of the vaccine candidate CIGB-66 against SARS-CoV-2 virus by parenteral route <b>Margarita COBA</b> Cuba	Mass balance in the quality control of synthetic peptides. An useful tool for consistency of the process <b>José MARCELO</b> Cuba	Characterization of polyribosylribitol phosphate by high efficiency size-exclusion chromatography with ultraviolet detection <b>Yaneyis MÉNDEZ</b> Cuba	Methodology for equipment cleaning validation and continuous verification on the Epidermal Growth Factor production process <b>Rebeca BOUYON</b> Cuba
	9:50 - 10:05	Study of adsorption of the RBD-Ppa protein to the IMAC-Cu matrix <b>Juliet PADRÓN</b> Cuba	Drinking water as raw material for biomanufacturing: analysis of physicochemical parameters to evaluate its quality <b>Rebeca VIZCAÍNO</b> Cuba	Risk assessment establishment of the P64Kr production process <b>Dania BACARDÍ</b> Cuba	Determination of critical process parameters in HBsAg manufacturing used as API in vaccine production <b>Yeny DE LA TORRE</b> Cuba
	10:10 - 10:25	Design and optimization of the lyophilization process of the Active Pharmaceutical Ingredient of immunomodulatory peptide Jusvinza® <b>Eliane BLANCO</b> Cuba	Design of a process validation test in fermenters. Comparison with fermenter sterility test conducted during performance qualification <b>Wilmot FERRERO</b> Cuba	Design of risk management matrices to validate aseptic process of the sterilizing filtration in a multi-product facility <b>Yaneyis ÁLVAREZ</b> Cuba	Some regulatory analysis applied to the manufacture of biologicals in a CIGB multiproduct facility <b>Natacha PÉREZ</b> Cuba
	10:30 - 10:45	Establishment by RP-HPLC of the purity test, for the analysis of the IFA of RBD, vaccine candidate against COVID-19 <b>Maylín La O</b> Cuba	Design and application of metrological supervision at the Center for Genetic Engineering and Biotechnology <b>Anabel PÉREZ</b> Cuba	Consistency analysis of the CB.Hep-1 immunosorbent large scale manufacturing process <b>Andrés TAMAYO</b> Cuba	Quality by Design: Reality or Utopia? <b>David DIAGO</b> Cuba
	10:50 - 11:05	Determination of RBD reference material isoelectric point used to release COVID-19 vaccine candidate API samples <b>Raydan LEMUS</b> Cuba	Reliability of measurements <b>Luis ÁLVAREZ</b> Cuba	New <i>in vitro</i> bioassay as part of the new trends in the quality control of biotechnological products: Heberprot-P® <b>Luisa GLENDA</b> Cuba	Use of risk analysis in manage changes in the biotechnological productions <b>Ivonne RODRÍGUEZ</b> Cuba
	11:10 - 11:25	Scaling-up of <i>Escherichia coli</i> fermentation process for recombinant P64k protein production <b>Denis ÁLVAREZ</b> Cuba	N-Terminal sequencing by Edman degradation implementation for the Identification of the pharmaceutical peptide CIGB-258 <b>Galina MOYA</b> Cuba	Synthesis and LC-MS/MS characterization of two vaccine candidates against ticks <b>Satomy POUSA</b> Cuba	Satisfactory execution of international simulation of product withdrawal from market with exported product together with the company Liof-Pharma <b>Kenia VÁZQUEZ</b> Cuba
	11:30 - 11:45	State of art of plantbody purification from transgenic plant. Plantbody HB-01 purification process as study case <b>Leonardo GÓMEZ</b> Cuba	Building automation systems, a new horizon for the Cuban biotechnology industry <b>David GOITZOLO</b> Cuba	Qualification and continuous validation of the compressed air system of a production plant <b>Adonis SENRA</b> Cuba	Microbiological evaluation of the environment and proposal of an environmental monitoring program for the introduction of a new product <b>Caridad SUAREZ</b> Cuba
	11:50 - 12:05	Comparison of two systems for the plantbody HB-01 purification from transgenic tobacco plant leaves <b>Williams FERRO</b> Cuba	Fermenter requalification strategy based on risk analysis <b>Carlos MARTÍNEZ</b> Cuba	Establishment of a chemically defined medium for the expression of P64Kr in <i>Escherichia coli</i> <b>Laura VARAS</b> Cuba	New flow of operations in the production plant of CIGB to improve good manufacturing practices <b>Maria TUÑÓN</b> Cuba
	12:10 - 12:25	Characterization of Sodium Periodate-Zetarose-CL4B in the Hepatitis B Surface Antigen Immunopurification <b>Airela LLAMO</b> Cuba	Validation of peptide CIGB500 protein determination by 280 nm spectrophotometric method <b>Rubén LÓPEZ</b> Cuba	Study on the separation by SDS-PAGE of IFN gamma with the conditions of the European Pharmacopoeia <b>Osniel CABRERA</b> Cuba	Application of the risk analysis to the production of the recombinant protein HBsAg expressed in <i>Pichia pastoris</i> <b>Rafael FERNÁNDEZ</b> Cuba
	12:30 - 12:45	Mouse hybridoma cell continuous culture in the Lambda-MINIFOR bioreactor using protein free media in hundred days <b>Hasel ARAGÓN</b> Cuba	A liquid chromatographic method for Thiomersal quantitation in raw materials and multidose vaccine formulation <b>Sussette PALACIO</b> Cuba	Qualification of a system that allows samples to be transported <b>Maria DENIS</b> Cuba	Establishment of the expanded bed chromatography technology for recovery stage the new vaccine production <b>Yadira VICENTE</b> Cuba
	12:50 - 1:05	<b>BIOCEN</b> Cuba Undefined yet			
1:20 - 4:15	<b>TRADE FIRM PRESENTATION IN DIGITAL FORMAT</b>				
4:15 - 5:00	<b>EXCHANGES WITH SPEAKERS OF RECORDED PRESENTATIONS</b>				